comparemela.com

Latest Breaking News On - துணை ப்ரெஸிடெஂட் ஆராய்ச்சி - Page 7 : comparemela.com

QUANTUM GENOMICS: Quantum Genomics Announces the Publication of New Scientific Article in Biomedecine et Pharmacotherapy which further strengthen its Phase III development plan in difficult to treat and resistant hypertension

(1) Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension and heart failure, announces the publication in Biomedecine &Pharmacotherapy of a new scientific peer-reviewed article reporting the efficacy of firibastat in combination with enalapril and hydrochlorothiazide in an experimental model of salt-sensitive hypertension (the DOCA-salt hypertensive rat). The article, entitled Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats is available online on the website of the journal Biomedecine -& Pharmacotherapy (Biomedicine & Pharmacotherapy - Journal - Elsevier DOI: 10.1016/j.biopha.2021.111682). The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-daily treatment

New-york
United-states
Paris
France-general
France
French
Catherine-llorens-cortes
Fabrice-balavoine
Mike-tattory
Linkedin
Twitter
France-french-national-institute-of-health

Documentary Of The Week: How Far To Low-Carbon Living?

On April 30 2021 Hauwei Technologies sponsored a program Great Minds Talk: How Far to Low-Carbon Living? The participants in this discussion were Lord Adair Turner, chair of the Energy Transitions Commission, Prof Steve Keen, Honorary Professor and Vice President Research, University College London, and Paul Scanlan, Chief Technology Officer, Huawei Carrier Business Group. The moderator is Rebecca Rice, Associate Director at BCW Global. Please share this article - Go to very top of page, right hand side, for social media buttons. Lord Turner chairs the Energy Transitions Commission, a global coalition of major power and industrial companies, investors, environmental NGOs and experts working out achievable pathways to limit global warming to well below 2˚C by 2040 while stimulating economic development and social progress.

Australia
Shanghai
China
Sydney
New-south-wales
United-kingdom
House-of-lords
Singapore
Cambridge
Cambridgeshire
University-college
London

Khủng hoảng chip có thể kéo dài tới 2023  - Thế giới số

Khủng hoảng chip có thể kéo dài tới 2023  - Thế giới số
vietgiaitri.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietgiaitri.com Daily Mail and Mail on Sunday newspapers.

China
Chinese
Europe
Firm-research
Pictured-today
Deputy-president-research
Iodine-all
Fine-under
Under-director-strategy
Global-outside
Explaining-hurricane
Chinese-before

Khủng hoảng chip có thể kéo dài tới 2023

Khủng hoảng chip có thể kéo dài tới 2023
ictnews.vietnamnet.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ictnews.vietnamnet.vn Daily Mail and Mail on Sunday newspapers.

Firm-research
Deputy-president-research
Iodine-all
Fine-under
Under-director-strategy
துணை-ப்ரெஸிடெஂட்-ஆராய்ச்சி

Compugen Reports First Quarter 2021 Results

Compugen Reports First Quarter 2021 Results USA - English Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701 triple combination study and COM902 monotherapy study in Q4 2021 Initiation of Phase 1b cohort expansion study of COM701 with Opdivo® in Q2 2021 and Phase 1 COM701 with COM902 dual combination study in 2H 2021 will expand systematic DNAM axis clinical evaluation News provided by Share this article Share this article HOLON, Israel, May 13, 2021 /PRNewswire/  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2021.

United-states
Israel
Tel-aviv
American
John-mullaly
Johns-hopkins-university
Lifesci-advisors
Society-for-immunotherapy-of-cancer
American-society-of-clinical-oncology
Compugen-ltd
Compugen
Nasdaq

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.